Aktuellt
SENASTE
Redeye retains its positive view of Carasent following the Q3 report. We believe the strong CARR and further growth prospects – boosted by the new surgical module, for example – and a limited need for increased OPEX set Carasent for solid organic growth and expanding margins over the next few years.
LÄS MER
